2016：

　　　　Identification of functional networks in E1E2 glycoproteins unveils Hepatitis C virus fusion mechanisms and new therapeutic opportunities. Douam F, Linda DIB, Schwaller L., Maurin G, Dao Thi VL, Cosset FL, Carbone A. and Lavillette D. In revision 

　　2015： 

　　　　Specialization of hepatitis C virus envelope glycoproteins for B-lymphocytes in chronically infected patients. Douam F, Bobay LM, Maurin G, Fresquet J, Calland N, Durand T, Cosset FL, Féray C and Lavillette D. J Virol. 2015 Nov 4. pii: JVI.02516-15. (IF2014 4,4) 

　　　　Marnata C, Saulnier A, Mompelat D, Krey T, Cohen L, Boukadida C, Warter L, Fresquet J, Vasiliauskaite I, Escriou N, Cosset FL, Rey FA, Lanford RE, Karayiannis P, Rose NJ, Lavillette D, Martin A. Determinants Involved in Hepatitis C Virus and GB Virus B Primate Host Restriction. J Virol. 2015 Dec 1;89(23):12131-44. doi: 10.1128/JVI.01161-15 (IF2014 4,4) 

　　　　Maurin G, Halgand B, Bruscella P, Fresquet J, Duclos-Vallée JC, Roque-Afonso AM, Cosset FL, Samuel D, Féray C*, Lavillette D*. Low cross neutralization of Hepatitis C virus correlates with liver disease in immunocompromized patients. AIDS. 2015 Jun 1;29(9):1025-33. (IF2013 6.55) 

　　2014： 

　　　　Girard-Gagnepain A, Amirache F, Costa C, Lévy C, Frecha C, Fusil F, Nègre D, Lavillette D, Cosset FL, Verhoeyen E. Baboon envelope pseudotyped lentiviral vectors outperform VSV-G pseudotyped lentiviral vectors for gene transfer into cytokine-stimulated and resting hematopoietic stem cells. Blood. 2014 Jun 20. pii: blood-2014-02-558163. (IF2012 9) 

　　　　Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A. Up-Regulation of the ATP-Binding Cassette Transporter A1 Inhibits Hepatitis C Virus Infection. PLoS One. 2014 Mar 19;9(3):e92140. (IF2012 3,7) 

　　　　Douam F, Dao Thi VL, Maurin G., Fresquet J., Mompelat D., Cosset FL and Lavillette D. A critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology. 2014 Mar;59(3):776-88 (IF2011 11,66). 

　　2012： 

　　　　Boo I, Tewierik K, Douam F, Lavillette D, Poumbourios P, Drummer HE. Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2. Biochem J. 2012 Apr 1;443(1):85-94. (IF2011 4.89) 

　　2011 

　　　　Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, Legrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2011 Aug 3;3(94):94ra71. (IF2011 .7,8) 

　　　　Maurin G, Fresquet J, Granio O, Wychowski C, Cosset FL and Lavillette D. Identification of interactions in the E1E2 heterodimer of Hepatitis C virus important for cell entry. J Biol Chem. 2011 Jul 8;286(27):23865-76. (IF2011 5.11) 

　　　　Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011 May;17(5):589-95. (IF2011 26,41)